Manual continuous positive airway pressure (CPAP) titration in a tions (9) can improve the efficiency with which CPAP treatsleep laboratory is costly and limits access for diagnostic studies. ment is delivered, as compared with conventional in-laboraMany factors affect CPAP compliance, but education and support, tory overnight CPAP titration. Given the high disease rather than in-laboratory CPAP titration, appear to be pivotal. Selfprevalence and limited healthcare resources, carefully evaluadjustment of CPAP at home will provide equal or superior efficacy ated attempts at greater efficiency in managing patients with ing treatment has been demonstrated to be successful in OSA who require CPAP treatment.
Although the level of educational support, disease severity, treatment response, and other factors have been identified Obstructive sleep apnea (OSA) is a common condition, afas contributors to CPAP compliance (17, 18) , each has acfecting 4% adult males and 2% adult females (1) . It is associcounted for only a small part of the variance in compliance ated with significant mortality and morbidity, and untreated among individuals. The latter fact and the unpredictability OSA imposes a substantial healthcare burden on the econof CPAP compliance among patients with OSA have led to omy (2). Since its original description in 1981 (3), continuous the belief that the individual patient's outlook on CPAP positive airway pressure (CPAP) has become the standard treatment may be of paramount importance in determining treatment for OSA. It is a particularly effective treatment CPAP compliance (17, 19) , which may seem intuitively obvifor patients with moderate or severe OSA (4) but also has ous, given the somewhat cumbersome nature of the device. demonstrable benefits in patients with mild OSA (5, 6).
We therefore designed an intraindividual crossover trial to CPAP titration to discern the optimal pressure required to compare outcomes between the conventional in-laboratory alleviate upper airway obstruction during sleep usually inmethod of CPAP titration and patient self-titration of CPAP cludes a simultaneous recording of sleep, respiration, and for OSA. oxygen saturation (7) and is typically conducted in a sleep laboratory. This practice is expensive (two overnight sleep METHODS laboratory studies per patient with OSA-diagnostic and CPAP titration) and limits access to the sleep laboratory for Design diagnostic studies. Recent evidence suggests that the use of A randomized, single-blind, two-period crossover design was employed, automated CPAP devices (8) and abbreviated CPAP titrawith a 1-week wash-in period off CPAP, two 5-week treatment limbs, and a 1-week washout between treatment limbs (Figure 1 ). On the "fixed limb," patients received CPAP at the pressure predetermined by manual in-laboratory titration and were not permitted to adjust the CPAP. On the "self-adjusting" limb, patients received CPAP preset at (Received in original form April 22, 2002 ; accepted in final form November 13, 2002) an estimated therapeutic pressure based on a prediction formula (20) Supported by a grant from the Department of Medicine at Queen's University and were encouraged to adjust the pressure as necessary to maximize and from an Ontario Thoracic Society Block Term Grant.
comfort and perceived efficacy. Upon entry, patients underwent manual in-laboratory CPAP titration by an experienced registered polysomno- 
Blinding Procedure

RESULTS
The pressure display on the CPAP unit was concealed throughout the The flow of patients through the study is illustrated in Figure 2. fixed limb of the study with tape and adhesive that could not be removed Eighteen patients (16 males and 2 females) completed the study.
by the patient. Sleep studies were scored blind by using a montage that These patients were 50 Ϯ 15 years old (mean Ϯ SD; range, excluded the CPAP signal. for OSA, facial/nasal CPAP appliances, and symptoms that would sugtate cancer during the study). One patient was withdrawn when gest an incorrect CPAP setting before randomization. Patients were it was discovered that although his diagnostic sleep study and shown how to adjust the CPAP before the self-adjusting CPAP treatbaseline sleep study on limb 1 both showed an AHI of more ment limb.
Outcome Measures
CPAP compliance (mean hours/night), CPAP employed (cm H 2 O), Apnea Hypopnea Index (AHI) (21), objective sleep architecture, Epworth Sleepiness Scale Score (22) , Sleep Apnea Quality of Life Index score (23), Functional Outcomes of Sleep Questionnaire (FOSQ) score (24) , Maintenance of Wakefulness Test (40-minute version) mean sleep onset latency (25) , and Trail Making B time(s) (26) .
Compliance
Each CPAP unit (Aria; Respironics Inc., Pittsburgh, PA) recorded runtime, time at prescribed pressure, and the CPAP setting daily. The actual CPAP output was measured independently after each limb.
Patients
Of 28 patients approached, 24 agreed to participate in the study. Of the 24 recruited patients, 6 did not complete the study; they were 52 Ϯ 12 years old (mean Ϯ SD, range 39 to 68 years), and had a mean body mass index of 37 Ϯ 9 kg/m 2 (range, 29-53 kg/m 2 ), an AHI on diagnostic sleep study of 65 Ϯ 31 (range, 28-93), a pretreatment Epworth score of 8.5 Ϯ 3.6 (range, 4-14), and a CPAP requirement (manual titration) of 11 Ϯ 2.2 cm H 2 O (range, 8-14 cm H 2 O).
Data Analysis
The treatment effect (adjusting limb-fixed limb) estimates for each outcome were calculated using the popular method described by Fleiss (27) and others for two-period crossover studies (see the online supplement). This method allows for a possible period effect and is appropriate when there is an imbalance in the number of patients randomized to each sequence. Point estimates of the treatment effects are presented with the corresponding 95% confidence intervals. than 20; his baseline study at the start of limb 2 (off CPAP)
CPAP Compliance
showed no evidence of OSA. As per the study protocol, the The average duration of CPAP use per night was not significantly patient had returned his CPAP unit to the investigators for the different between the fixed (6.4 Ϯ 1.2 hours) and self-adjusting duration of the washout period. The disappearance of OSA in (6.7 Ϯ 1.7 hours) limbs of the study with a mean within patient his case remains unexplained. However, the patient's spouse had difference of 0.3 (Ϫ0.6 to 1.2 hours, p ϭ 0.48). CPAP was not a CPAP unit at home, and it is possible that the patient used this used during an average of 1.9 Ϯ 2.4 days on the fixed limb and unit during the washout period. One patient withdrew because of 2.3 Ϯ 3.4 days on the self-adjusting limb for a difference of 0.45 nasal discomfort from CPAP treatment. Two patients withdrew (Ϫ2.1 to 3.0 days, p ϭ 0.71). Analysis of the hours of CPAP use because of scheduling conflicts between work and research testduring only those nights when the device was actually applied ing. One patient chose not to provide an explanation for withreveals a mean CPAP use per night on the fixed study limb of drawal from the study.
6.7 Ϯ 1.1 hours and on the self-adjusting limb of 7.3 Ϯ 2.2 hours, resulting in a difference of 0.6 (Ϫ0.5 to 1.6 hours/night, p ϭ CPAP 0.28). Patients used CPAP for more than 4 hours on 87 Ϯ 14% of the fixed limb nights and 86 Ϯ 10% of the self-adjusting limb The CPAP determined by patients to be optimal during the selfnights. adjusting limb of the study was 10.1 Ϯ 2.0 cm H 2 O (mean Ϯ SD, range, 7 to 14 cm H 2 O) compared with 9.7 Ϯ 2 cm H 2 O
Subjective Outcome Measures
(range, 7 to 13 cm H 2 O) derived by manual overnight CPAP There were significant improvements in most of the subjective titration in the sleep laboratory. The estimated within patient outcome measures during both treatment limbs (Table 1) . In difference between these values was 0.3 (95% confidence interparticular, substantial improvements in subjective sleepiness and val, Ϫ0.6 to 1.3 cm H 2 O, p ϭ 0.45). The agreement between the disease-specific quality of life were noted. However, there was optimal CPAP chosen by the patient and that derived by inno difference in the size of the improvement observed between laboratory titration (r ϭ 0.62, p ϭ 0.006) is depicted in Figure 3 . the two treatment limbs for any of these variables. The mean prediction equation-derived optimal CPAP (8.5 Ϯ 0.4 cm H 2 O, range, 6 to 13 cm H 2 O), which was used as the
Objective Outcome Measures
starting pressure for the self-adjusting limb of the study, was Table 2 demonstrates the overnight polysomnographic data for significantly different from the mean self-determined optimal the 4 overnight polysomnograms performed on each of the 18 CPAP at the end of that treatment limb (mean difference 1.6 Ϯ patients. There was no statistically significant difference in the 1.2 cm H 2 O; 95% confidence interval, 1 to 2.2 cm H 2 O; p Ͻ change in any of the sleep variables between the two treatment 0.0001), but the two pressures were significantly correlated (r ϭ limbs. The sleep stage architecture did not change significantly 0.82, p Ͻ 0.001). Similarly, the mean prediction equation-derived with either CPAP treatment limb. As expected, there were pro-CPAP differed significantly from the mean in-laboratory deterfound improvements in minimum oxygen saturation and AHI mined CPAP (mean difference, 1.2 Ϯ 1.8 cm H 2 O, p ϭ 0.012), with both CPAP treatment limbs, but no significant difference but the two were significantly correlated (r ϭ 0.63, p ϭ 0.005).
between treatment limbs. On the self-adjusting CPAP limb, the average number of CPAP Daytime Alertness and Trail-making Performance changes made by patients was 5.7 (SEM 1.0; range, 1 to 16). No adjustment of the CPAP occurred during the fixed limb in any CPAP treatment on both limbs of the study was accompanied by a significant improvement in objective daytime alertness, as patient. Mean Ϯ SD values for variables at the start and end of the fixed and self-adjusting CPAP treatment limbs. ⌬ Fixed refers to the change in the variable between the start and end of the fixed limb. ⌬ Adjust refers to the change in the variable between the start and end of the self-adjusted limb. Adjusted ⌬ Ϫ Fixed ⌬ refers to differences between ⌬ Fixed and ⌬ Adjust for each variable.
TABLE 1. MEAN VALUES FOR OUTCOME VARIABLES ON EACH LIMB
measured by the Maintenance of Wakefulness Test (Table 1) .
and compliance with CPAP treatment was highly satisfactory on both study limbs. However, there was no significant difference between treatment
The observed improvements in subjective outcome measures limbs in the mean improvement in this variable. The Trails B during both treatment limbs were of similar magnitude to those test score did not change significantly with treatment during previously documented with CPAP treatment in moderate and either of the two study limbs, and there was no difference in severe OSA. Thus, the change in subjective sleepiness as meathe mean change in trail-making performance between the two sured by the Epworth Sleepiness Scale score during each treattreatment limbs. ment limb in this study was similar to that observed in clinical practice (18) and in placebo-controlled trials of CPAP treatment
DISCUSSION
for OSA (5, 28, 29) . The Sleep Apnea Quality of Life Index is This study demonstrates that patients with OSA are capable of a useful measure of disease-specific quality of life and, in particueffective self-titration of CPAP treatment at home. The optimal lar, has the ability to incorporate negative effects of CPAP into CPAPs, defined by self-titration and by manual in-laboratory the overall pre-to post-CPAP response (23). The size of the titration, were similar. Improvements in both subjective and mean improvement in the Sleep Apnea Quality of Life Index objective outcome measures were fairly consistent and were score with CPAP treatment in both limbs of this study (0.8 units, similar in magnitude between self-titration at home and manual fixed CPAP limb; 1.1 units, self-adjusted CPAP limb) represents in-laboratory CPAP titration during overnight polysomnograa small but clinically significant improvement (30) . There was a phy. There was no clinically significant difference in any measlightly greater improvement in Sleep Apnea Quality of Life Index score with self-adjusted CPAP than with in-laboratory sured outcome between the two CPAP treatment modalities, Definition of abbreviations: CI ϭ confidence interval; RDI ϭ respiratory disturbance index; REM ϭ rapid eye movement sleep; Sa O 2 ϭ oxygen saturation; TST ϭ total sleep time.
Mean Ϯ SD values for objective sleep variables at the start and end of the fixed and self-adjusted CPAP treatment limbs. Adjusted ⌬ Ϫ Fixed ⌬ estimates the difference between the changes in the fixed and adjusting limbs. None of these differences were significant at ␣ ϭ 0.05.
* p Ͻ 0.01 for the change from pre to post for both fixed and self adjusting limbs.
titrated CPAP, but the difference between CPAP treatment in objective sleep architecture in patients with OSA with CPAP treatment. Others have described improvements in symptoms modes was not clinically important. The CPAP treatment-associated change in the FOSQ (24) score observed during each limb of and daytime performance in patients with OSA treated with CPAP, in the absence of any objective improvement in sleep the current study was significant and consistent with the findings reported in other trials of CPAP treatment for OSA (28, 29) . architecture (6), but this finding is not typical. This study was not specifically designed to examine differences in sleep stage Thus, patients with mild OSA had fewer symptoms (a higher baseline pretreatment FOSQ score, mean 101 Ϯ SD) (18) and architecture with treatment (sleep stage data were required to calculate the pretreatment and post-treatment AHIs and were a smaller response to CPAP treatment (mean post-CPAP treatment FOSQ score, 106 Ϯ 18) than that observed during either therefore reported). McArdle and Douglas, in a placebo-controlled crossover study of 22 patients, designed to analyze the CPAP treatment limb in this study (29) , whereas patients with more severe OSA tended to have a more symptoms (a lower sleep architectural changes associated with treatment of OSA, demonstrated a doubling of slow wave sleep, halving of stage 1 pre-CPAP FOSQ score, mean Ϯ SEM, 84.5 Ϯ 4.63) and a larger pre-to post-CPAP treatment response in FOSQ score (postsleep, and a nonsignificant increase in REM sleep with CPAP treatment (36). Post hoc statistical power analysis reveals that CPAP score, 109.4 Ϯ 2.6) (28) than that observed in this study. The magnitude of the improvement in subjective outcome meathis study had 90% power (␣ ϭ 0.05) to detect a change of 5% in the proportion of total sleep time spent in slow wave sleep sures with either CPAP treatment limb in this study, therefore, was at least as great as that which might have been predicted, pre-to post-CPAP on either treatment limb or between the two post-CPAP nights in this study (an amount similar to the mean based on published literature in similar patient groups with OSA, suggesting that both treatment limbs provided effective sympdifference observed by McArdle and Douglas between CPAP and placebo). However, there was more variability in the pertomatic treatment to this patient group. However, it is important to understand that this patient group was not selected on the centage of time spent in stage 1 sleep pre-to post-CPAP treatment in this study. The post hoc power estimate suggests that a basis of symptom severity and included several patients who had few daytime symptoms; if subjective outcomes had been the most difference of 8% in the proportion of total sleep time spent in stage 1 sleep comparing pre-to post-CPAP and comparing the important outcome measures, then the presence of significant daytime symptoms related to OSA would have been an essential two post-CPAP nights would be required to provide 90% statistical power (␣ ϭ 0.05) in this study; this is a larger change than inclusion criterion.
Most objective outcome measures also improved significantly that observed by McArdle and Douglas. Hence, an inadequate sample size may underlie the apparent lack of improvement in with either method of CPAP treatment. The Maintenance of Wakefulness Test (31, 32) was employed as a measure of daytime some aspects of sleep architecture in this study. The use of a crossover design increased statistical power to alertness in this study, as evidence suggests that it is a more valid measure of sleepiness/alertness in OSA than the Multiple detect differences in the primary outcome variables of this study, but the major motivation for this design was to eliminate the Sleep Latency Test (31) (32) (33) . Using the one-epoch criterion for sleep onset and the 40-minute version of the test, patients were effect of interindividual differences on study outcomes, particularly CPAP compliance. CPAP compliance among patients with clearly objectively somnolent pretreatment on both limbs of the study, but voluntary alertness improved into the normal range OSA is a complex issue. Although severity of disease and improvement in daytime somnolence with treatment have been (25) with treatment, as expected. Trail-making B performance, a test of higher executive function, has demonstrated sensitivity demonstrated to be important factors in determining CPAP compliance (37), interindividual attitudes and preferences appear to in some previous studies to the effects of sleep apnea (26) and to CPAP treatment versus placebo (34) but did not show any be even more predominant in this regard (19) . Thus, despite a wealth of literature on factors associated with either satisfactory significant change with CPAP treatment in this study. However, the finding of improved trail-making performance with treator poor CPAP compliance among patients with OSA, it remains very difficult to predict CPAP compliance in a given patient with ment of OSA has not been a consistent one (35) , with several studies demonstrating no change in Trail-making performance OSA. This fact has fuelled enthusiasm for a purely pragmatic approach to CPAP treatment in OSA: A short individual clinical with treatment of OSA, despite unequivocal treatment-related improvements in several other domains. Therefore, it would trial of CPAP has been advocated as the best way of determining the likelihood of acceptable CPAP compliance in a given individbe unreasonable to extrapolate from the negative trail-making performance response to CPAP treatment in this study to other ual (38) . Whereas an intraindividual crossover design eliminated concerns about dominant interindividual differences in attitude domains of cognitive performance that were not measured in this study.
to and acceptance of CPAP treatment, it also opened up other potential sources of bias in this study. In particular, acclimatizaThe disparity between the aforementioned improvements in subjective and objective outcome measures and the lack of tion to CPAP treatment in the first study limb could have biased toward a greater treatment effect in the second study limb, and change in any objective measures of sleep architecture with CPAP treatment in this study is surprising. There was a marked a carryover effect between treatment limbs could have reduced the treatment effect on the second treatment limb. We attempted improvement in sleep continuity associated with reduction in the AHI and also a marked improvement in the nadir of the to address these potential sources of bias by (1 ) designing a washout period between treatment limbs that would eliminate oxygen saturation during sleep with treatment. One might have expected a coincident increase in slow wave sleep and rapid eye any likelihood of a carryover effect, (2 ) randomizing the treatment order between patients, (3 ) including possible order effects movement sleep with this magnitude of improvement in sleepdisordered breathing (21). The lack of improvement in objecin the data analysis when comparing outcomes between treatment limbs, (4 ) making baseline pretreatment measurements at tively measured sleep stage architecture with CPAP treatment in this study is not easy to explain. The noise to signal ratio of the start of each treatment limb to document any change in pretreatment disease severity between study limbs, and (5 ) comin-laboratory recordings could potentially have interfered with the ability to detect changes in sleep architecture, but the reparing the pretreatment to post-treatment change in relevant variables rather than simply comparing the post-treatment values cording equipment and environment used in this study were standard for clinical sleep studies and were similar to those for each variable. There are, of course, other cost-efficient methods of introducing CPAP treatment to patients with OSA. For employed in other studies that have demonstrated improvements patients with more severe OSA, split-night studies (where the study protocol empowered each patient with the knowledge and capability of directing his or her own CPAP treatment during overnight study is partitioned into an initial diagnostic part and then, after the diagnosis of OSA has been objectively confirmed, the self-adjusted CPAP treatment limb. This strategy has not previously been employed in CPAP treatment of OSA, but sys-CPAP titration is performed) have proven feasible (9, 39) . CPAP titration can also be undertaken by automated CPAP treatment tematic evaluations of similar management approaches for other medical disorders have generated very positive findings and have devices, and those devices that base the change in CPAP on changing airflow contour may provide a satisfactory estimation been demonstrated to facilitate cost-effective treatment of those conditions (16, (51) (52) (53) . Because CPAP compliance is already of the therapeutic CPAP in some patients (40) (41) (42) Automated CPAP titration devices do not appear to have any advantage known to be sensitive to patient education, it would be unethical and clinically unhelpful to have conducted a placebo-controlled over conventional fixed CPAP in the routine treatment of OSA (43) (44) (45) and may not compensate appropriately for changes in study of this educational intervention. The very satisfactory CPAP compliance rate with the conventional approach to CPAP nasal resistance (8) . A strategy that empowers the patient with OSA with the freedom to alter CPAP appropriately in response prescription in this study provided a suitably high treatment standard against which to evaluate self-directed CPAP therapy to altered upper airway physiology is inexpensive and may prove advantageous in the latter situation and in the long-term manageand provided information that will, hopefully, be useful in clinical practice. The study was adequately powered to detect clinically ment of the patient. To date, detailed objective measures of daytime performance in patients with OSA after automated meaningful differences between the two CPAP treatment strategies. One shortcoming of this study is the relatively short dura-CPAP titration have not been reported, and there is no available information, of course, on the relative merits of self-titration of tion of the treatment protocol; although the results are promising, they cannot be extrapolated to long-term clinical outcomes. CPAP versus automated CPAP titration.
In considering the findings of this study, it is important to A randomized parallel group study with a longer treatment duration, and with both clinical and health-economic outcomes, appreciate that the protocol required each patient to undergo a manual in-laboratory CPAP titration after randomization. It would be required to assess whether such a treatment strategy can provide significant economic advantages without comprois likely that patients derived some benefit from the presence of a sleep technologist during this initial exposure to CPAP.
mise of the standard of care for patients with OSA. In summary, this study demonstrates that self-titration of Indeed, there is very clear evidence that even minor initial efforts at encouragement and education of the patient with sleep apnea CPAP in patients with OSA is as efficacious as manual titration in a sleep laboratory, with similar subjective and objective outmay influence subsequent CPAP compliance (46, 47) . Patients in this study also received 30 minutes of education about sleep comes, and CPAP compliance. Clearly, for this strategy to be successful, the patient must understand when and how to change apnea and CPAP treatment and a phone call from a research assistant on each study limb. The latter level of patient education the CPAP. Although the patient population studied did include a wide age range, this strategy would not be feasible for intellecand support, which is equivalent to the routine allotment of time for education of each patient with a new diagnosis of OSA in tually disadvantaged patients and those with physical handicaps that would severely limit vision and/or manual dexterity. Noneour clinical practice, may nonetheless account for the superior CPAP compliance observed during both limbs of this study as theless, the findings from this study imply that routine overnight polysomnography is unnecessary for the purpose of CPAP titracompared with other similar controlled trials of CPAP treatment in OSA (4, 6, 48, 49). Hence, it is important not to misconstrue tion in many patients with OSA, provided that the patient is given some basic education and support. Resources currently the findings of this study as obviating the need for education and support of the patient with OSA undergoing CPAP treatment.
allocated to manual in-laboratory CPAP titration might be better spent on specific attention to patient education and support Rather, the study demonstrates that in combination with a modest amount of educational support (a time commitment from a rather than pressure titration. A treatment algorithm that focuses on such ambulatory patient education and support rather than clinical assistant that would, hopefully, be feasible in routine clinical practice), the patient with OSA is just as capable of in-laboratory CPAP titration may realize significant efficiencies in the management of OSA without loss of treatment efficacy. performing an effective CPAP self-titration as a technologist during overnight polysomnography. Although the self-determined optimal CPAP sometimes varied widely from the predic-have provided a useful starting point for patient self-titration it is important to bear this fact in mind when extrapolating the 858-865. findings of this study to patients whose sleep apnea diagnosis is 
